Abciximab

Literature References: Platelet aggregation inhibitor. Fab fragment of chimeric human-murine monoclonal antibody c7E3 directed against the human platelet glycoprotein IIb/IIIa (GPIIb/IIIa) receptor. Chimeric fragment consists of the variable regions of murine 7E3 reconstructed with human constant regions of the Fab fragment. Mol wt ~47,600. Prepn: B. S. Coller, D. M. Knight, WO 9512412 (1995 to Centocor and Res. Found. State Univ. New York); D. M. Knight et al., Mol. Immunol. 32, 1271 (1995). Pharmacology: C. Kohmura et al., Arterioscler. Thromb. 13, 1837 (1993). Clinical pharmacodynamics: J. E. Tcheng et al., Circulation 90, 1757 (1994). Clinical studies as adjunct in prevention of ischemic complications associated with coronary revascularization: EPIC Investigators, N. Engl. J. Med. 330, 956 (1994); EPILOG Investigators, ibid. 336, 1689 (1997). Review of development, binding studies and preclinical testing: R. E. Jordan et al. in Adhesion Receptors as Therapeutic Targets, M. A. Horton, Ed. (CRC Press, Boca Raton, 1996) p 281-305; of pharmacology and clinical efficacy: R. H. Foster, L. R. Wiseman, Drugs 56, 629-665 (1998).